Breakthrough TMVr Therapy
for High-Surgical-Risk Patients
MitraClip is the world’s first transcatheter mitral valve repair (TMVr) therapy that delivers a treatment option for patients with mitral regurgitation who would otherwise go untreated.¹,²
Over 70,000 patients worldwide* have been treated with MitraClip therapy, with 17,000 patients† followed through multiple studies and registries.
*Worldwide data as of November 2018, on file at Abbott.
†Total patients from Abbott sponsored studies, TVT registry, TRAMI, Reshape HF2,
Matterhorn, Mitra-FR, GRASP.
The MitraClip procedure is a minimally invasive catheter-based therapy performed by multidisciplinary Heart Teams.1 Open-heart surgery to repair or replace the mitral valve is generally recommended, but it is not an option for many patients.
TMVr with MitraClip therapy delivers a treatment option for patients who are not good surgical candidates.1-3
AP2947039-WBO Rev. A
- MitraClip NTR XTR Clip Delivery System Instructions for Use.
- Lim DS, et al. Improved functional status and quality of life in prohibitive surgical risk patients with degenerative mitral regurgitation after the transcatheter mitral valve repair. J Am Coll Cardiol. 2014;64(2):182-192.
- Baumgartner H, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease: The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J.2017;38(21):2739-2791.